Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. (Q34130665)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. |
scientific article |
Statements
Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer (English)
Suresh S Ramalingam
R Donald Harvey
Nabil Saba
John Kauh
Dong M Shin
Shi-Yong Sun
Sandra Strychor
Mourad Tighiouart
Merrill J Egorin
1 August 2010
1 reference
1 reference
1 reference